Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody eculizumab has received accelerated approval from the FDA for the treatment of pediatric ...

June 7, 2012 (Paris, France) — Children with atypical hemolytic-uremic syndrome (aHUS) had a robust response to eculizumab (Soliris) in real-life clinical settings. The finding mirrors clinical trial ...

LONDON, United Kingdom — For patients with atypical hemolytic uremic syndrome (HUS), the improvement in estimated glomerular filtration rate (eGFR) is significantly better when eculizumab (Soliris, ...

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards developing 5+ ...

AGNSS Recommends Soliris® (eculizumab) for aHUS and Concludes “Eculizumab would help save lives and improve the quality of life for children and adults with atypical haemolytic uraemic syndrome” ...

"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...

Please provide your email address to receive an email when new articles are posted on . Registry data showed efficacy of ravulizumab was similar to that of eculizumab. No unexpected adverse events ...

PARSIPPANY, N.J. and INCHEON, Korea, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Samsung Bioepis Co., ...

The Key Atypical Hemolytic Uremic Syndrome Companies in the market include - Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others. The Atypical Hemolytic Uremic ...

INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies have ...